How Might We Cure HIV?

BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism

(2013) Daniela Boehm et al.   CELL CYCLE

Therapeutic Vaccination Expands and Improves the Function of the HIV-Specific Memory T-Cell Repertoire

(2013) Joseph P. Casazza et al.   JOURNAL OF INFECTIOUS DISEASES

Targeting I B Proteins for HIV Latency Activation: the Role of Individual I B and NF- B Proteins

(2013) G. Fernandez et al.   JOURNAL OF VIROLOGY

Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo

(2013) E. J. Beans et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HIV-1 transcription and latency: an update

(2013) Carine Van Lint et al.   Retrovirology

A Dendritic Cell-Based Vaccine Elicits T Cell Responses Associated with Control of HIV-1 Replication

(2013) F. Garcia et al.   Science Translational Medicine

Bromodomain Proteins in HIV Infection

(2013) Daniela Boehm et al.   Viruses-Basel

Altering cell death pathways as an approach to cure HIV infection

(2013) A D Badley et al.   Cell Death & Disease

Quantitation of integrated proviral DNA in viral reservoirs

(2013) Erin H. Graf et al.   Current Opinion in HIV and AIDS

Prospects for Treatment of Latent HIV

(2012) K M Barton et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation

(2012) Liang Shan et al.   IMMUNITY

BET bromodomain inhibition as a novel strategy for reactivation of HIV-1

(2012) Camellia Banerjee et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

(2012) N. M. Archin et al.   NATURE

Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro

(2012) Brian A. DeChristopher et al.   Nature Chemistry

The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation

(2012) Zichong Li et al.   NUCLEIC ACIDS RESEARCH

Reactivation of Latent HIV-1 by Inhibition of BRD4

(2012) Jian Zhu et al.   Cell Reports

mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients

(2011) Ellen Van Gulck et al.   AIDS

Curing HIV: Pharmacologic Approaches to Target HIV-1 Latency

(2011) Shailesh K. Choudhary et al.   Annual Review of Pharmacology and Toxicology

HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo

(2011) A. G. Chapuis et al.   BLOOD

HIV-specific CD4 T cells and immune control of viral replication

(2011) Filippos Porichis et al.   Current Opinion in HIV and AIDS

Bryostatin-1 Synergizes with Histone Deacetylase Inhibitors to Reactivate HIV-1 from Latency

(2010) Moises Perez et al.   CURRENT HIV RESEARCH

Bryostatin Modulates Latent HIV-1 Infection via PKC and AMPK Signaling but Inhibits Acute Infection in a Receptor Independent Manner

(2010) Rajeev Mehla et al.   PLoS One

Immunotoxin Complementation of HAART to Deplete Persisting HIV-Infected Cell Reservoirs

(2010) Edward A. Berger et al.   PLoS Pathogens

Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy

(2009) Jean-Pierre Routy et al.   CLINICAL IMMUNOLOGY